Top

Published in:

01-08-2008 | Current Status

Review of Fecal Biomarkers in Inflammatory Bowel Disease

Authors: Andrew D. Sutherland, M.B.B.S., F.R.A.C.S., Richard B. Gearry, M.B.Ch.B., Ph.D., F.R.A.C.P., Frank A. Frizelle, M.B.Ch.B., M.Med.Sc., F.R.A.C.S

Published in: Diseases of the Colon & Rectum | Issue 8/2008

Abstract

Purpose

We reviewed potential fecal biomarkers of inflammatory bowel disease and assessed their utility in a range of clinical applications.

Methods

A literature search using PubMed, MEDLINE, and Embase database was performed, locating all language articles on fecal biomarkers, including calprotectin and lactoferrin. The references of these papers were searched manually for further references.

Results

A wide range of fecal biomarkers have been evaluated in the research setting. Only fecal calprotectin and lactoferrin have translated into useful clinical tools. These biomarkers have demonstrated high sensitivity for organic intestinal disease and good correlation with other measures of disease activity in inflammatory bowel disease.

Conclusions

Fecal calprotectin and lactoferrin are useful triage tools to differentiate organic intestinal disorders from functional disorders. They also have a role in monitoring inflammatory bowel disease activity and predicting relapse.

Desai D, Faubion WA, Sandborn WJ. Review article: biological markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007;25:247–55.PubMed

Angriman I, Scarpa M, D’Incà R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta 2007;381:63–8.PubMedCrossRef

Klass HJ, Neale G. Serum and fecal lysozyme in inflammatory bowel disease. Gut 1978;19:233–9.PubMedCrossRef

Langhorst J, Elsenbruch S, Mueller T, et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 2005;11:1085–91.PubMedCrossRef

Saiki T. Myeloperoxidase concentrations in the stool as a new parameter of inflammatory bowel disease. Kurume Med J 1998;45:69–73.PubMed

Adeyemi EO, Hodgson HJ. Fecal elastase reflects disease activity in active ulcerative colitis. Scand J Gastroenterol 1992;27:139–42.PubMedCrossRef

van der Sluys Veer A, Brouwer J, Biemond I, et al. Fecal lysozyme in assessment of disease activity in inflammatory bowel disease. Dig Dis Sci 1998;43:590–5.PubMedCrossRef

Silberer H, Kuppers B, Mickisch O, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab 2005;51:117–26.PubMed

Peterson CG, Eklund E, Taha Y, Raab Y, Carlson M. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol 2002;97:1755–62.PubMedCrossRef

10.

Biancone L, Fantini M, Tosti C, et al. Fecal alpha-1-antitrypsin clearance as a marker of clinical relapse in patients with Crohn’s disease of the distal ileum. European J Gastroenterol Hepatol 2003;15:261–6.CrossRef

11.

Choudari CP, O’Mahony S, Brydon G, Mwantembe O, Ferguson A. Gut lavage fluid protein concentrations: objective measures of disease activity in inflammatory bowel disease. Gastroenterology 1993;104:1064–71.PubMed

12.

Saverymuttu SH, Camilleri M, Rees H, et al. Indium-111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease: a comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology 1986;90:1121–8.PubMed

13.

Røseth AG, Schmidt PN, Fagerhol MK. Correlation between fecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50–4.PubMedCrossRef

14.

Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 2000;47:506–13.PubMedCrossRef

15.

D’Incà R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007;22:429–37.PubMedCrossRef

16.

Bremner A, Roked S, Robinson R, Phillips I, Beattie M. Fecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr 2005;94:1855–8.PubMedCrossRef

17.

Røseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by fecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176–80.PubMedCrossRef

18.

Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793–8.PubMedCrossRef

19.

Kane SV, Sandborn WJ, Rufo PA, et al. Fecal Lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003;98:1309–14.PubMedCrossRef

20.

Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996;91:927–34.PubMed

21.

Uchida K, Matsuse R, Tomita S, Sugi O, et al. Immunochemical detection of human lactoferrin in feces as a new marker of inflammatory gastrointestinal disorders and colon cancer. Clin Biochem 1994;27:259–64.PubMedCrossRef

22.

Grill BB, Hillemeier AC, Gryboski JD. Fecal alpha-1-antitrypsin clearance in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1984;3:56–61.PubMed

23.

van der Sluys Veer A, Biemond I, Verspaget HW, Lamers CB. Fecal parameters in the assessment of activity of inflammatory bowel disease. Scand J Gastroenterol 1999;34(Suppl 230):106–10.CrossRef

24.

Meyers S, Wolke A, Field SP, et al. Fecal alpha-1-antitrypsin measurement: An indicator of Crohn’s disease activity. Gastroenterology 1985;89:13–8.PubMed

25.

Segal AW, Ensell J, Munro JA, Sarner M. Indium-111-tagged leukocytes in the diagnosis of inflammatory bowel disease. Lancet 1981;ii:230–2.CrossRef

26.

Saverymuttu SH, Peters AM, Crofton ME, et al. 111 Indium labelled autologous granulocytes in the detection of inflammatory bowel disease. Gut 1985;26:955–60.PubMedCrossRef

27.

Saverymuttu SH, Hodgson HJ, Chadwick VS. Comparison of fecal granulocyte excretion in ulcerative colitis and Crohn’s colitis. Dig Dis Sci 1984;29:1000–4.

28.

Steinbakk M, Naess-Andresen C-F, Lingaas E, et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990;336:763–5.PubMedCrossRef

29.

Fagerhol MK, Dale I, Anderson I. Release and quantification of leukocyte derived protein (L1). Scand J Haematol 1980;24:393–8.

30.

Ton H, Brandnes O, Dale S, et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41–54.PubMedCrossRef

31.

Buderus S, Boone J, Lyerly D, Lentze MJ. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Digestive Dis Sci 2004;49:1036–9.CrossRef

32.

Parsi MA, Shen B, Achkar JP, et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 2004;126:1280–6.PubMedCrossRef

33.

Bernier JJ, Florent C, Desmazures C, Aymes C, L’Hirondel C. Diagnosis of protein losing enteropathy by gastrointestinal clearance of alpha-1-antitrypsin. Lancet 1978;2:763–4.PubMedCrossRef

34.

Florent C, L’Hirondel C, Desmazures C, Giraudeaux V, Bernier JJ. Evaluation of ulcerative colitis and Crohn’s disease activity by measurement of alpha-1-antitrypsin intestinal clearance. Gastroenterol Clin Biol 1981;5:193–7.PubMed

35.

Lundberg JO, Hellström PM, Fagerhol MK, Weitzberg E, Røseth AG. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease. Gastroenterol Hepatol 2005;2:96–102.

36.

Lundberg JO, Hellström PM, Lundberg JM, Alving K. Greatly increased luminal nitric oxide in ulcerative colitis. Lancet 1994;344:1673–4.PubMedCrossRef

37.

Perner A, Nordgaard I, Matzen P, Rask-Madsen J. Colonic production of nitric oxide gas in ulcerative colitis, collagenous colitis and uninflamed bowel. Scand J Gastroenterol 2002;37:183–8.PubMedCrossRef

38.

Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999;45(Suppl 2):II43–7.PubMedCrossRef

39.

Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450–60.PubMedCrossRef

40.

Canani RB, de Horatio LT, Terrin G, et al. Combined use of non-invasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2006;42:9–15.PubMedCrossRef

41.

Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003;49:861–7.PubMedCrossRef

42.

von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803–13.CrossRef

43.

Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB. Diagnostic accuracy of fecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004;20:615–21.PubMedCrossRef

44.

Tibble J, Sigthorsson G, Foster R, et al. Fecal calprotectin and fecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001;49:402–8.PubMedCrossRef

45.

Hoff G, Grotmol T, Thiis-Evensen E, et al. Testing for fecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 2004;53:1329–33.PubMedCrossRef

46.

Poullis A, Foster R, Shetty A, Fagerhol MK, Mendall MA. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2004;13:279–84.PubMedCrossRef

47.

Fagerberg UL, Lööf L, Myrdal U, Hansson L-O, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005;40:450–5.PubMedCrossRef

48.

Fagerberg UL, Lööf L, Merzoug RD, Hansson L-O, Finkel Y. Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr 2003;37:468–72.PubMedCrossRef

49.

Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 2001;7:460–5.PubMed

50.

Røseth AG, Aadland E, Grzyb K. Normalization of fecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1017–20.PubMedCrossRef

51.

Gomes P, Du Bolay C, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986;27:92–5.PubMedCrossRef

52.

Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15–22.PubMedCrossRef

53.

Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 2005;54:364–8.PubMedCrossRef

54.

Scarpa M, D’Inca R, Basso D, et al. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn’s disease. Dis Colon Rectum 2007;50:861–9.PubMedCrossRef

55.

Parsi MA, Ellis JJ, Lashner BA. Cost-effectiveness analysis of fecal lactoferrin assay as the initial diagnostic approach to symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 2004;128(Suppl 2):A208.

56.

Thomas P, Rihani H, Røseth A, et al. Assessment of ileal pouch inflammation by single stool calprotectin assay. Dis Colon Rectum 2000;43:214–20.PubMedCrossRef

Title: Review of Fecal Biomarkers in Inflammatory Bowel Disease
Authors: Andrew D. Sutherland, M.B.B.S., F.R.A.C.S.
Richard B. Gearry, M.B.Ch.B., Ph.D., F.R.A.C.P.
Frank A. Frizelle, M.B.Ch.B., M.Med.Sc., F.R.A.C.S
Publication date: 01-08-2008
Publisher: Springer-Verlag
Published in: Diseases of the Colon & Rectum / Issue 8/2008
Print ISSN: 0012-3706
Electronic ISSN: 1530-0358
DOI: https://doi.org/10.1007/s10350-008-9310-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Review of Fecal Biomarkers in Inflammatory Bowel Disease

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2008

The Oblique Rectus Abdominal Myocutaneous Flap for Complex Pelvic Wound Reconstruction

Adenoma Detection Rate: The Real Indicator of Quality in Colonoscopy

Hemorrhoids can be a Source of Obscure Gastrointestinal Bleeding that Requires Transfusion: Report of Five Patients

Sphincter-Sparing Surgical Alternatives for Chronic Anal Fissure: the Place of Fissurotomy

Evaluation of Rectal Sensory and Motor Function by Means of the Electronic Barostat After Stapled Hemorrhoidopexy

Associations Between Exercise, Quality of Life, and Fatigue in Colorectal Cancer Survivors